<DOC>
	<DOC>NCT00300378</DOC>
	<brief_summary>The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.</brief_summary>
	<brief_title>Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>A primary diagnosis of MDD Depressive symptoms for at least 30 days before the screening visit. Treatment with DVS SR at any time in the past. Known hypersensitivity to venlafaxine Significant risk of suicide based on clinical judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Depression</keyword>
	<keyword>Adult</keyword>
	<keyword>Outpatients</keyword>
</DOC>